Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Strategic Spin-off | Explore BDX's plan to separate its Life Sciences division, potentially unlocking $16.7 billion in equity value and reshaping the company's future growth trajectory. |
Financial Resilience | Delve into BDX's robust Q1 FY2025 performance, surpassing expectations with $5,168 million in revenue and $3.43 EPS, showcasing the company's financial strength. |
Market Sentiment | Analysts offer diverse perspectives on BDX, with price targets ranging from $185 to $280, reflecting varied outlooks on the company's growth potential and strategic moves. |
Growth Catalysts | Learn about BDX's opportunities in emerging markets, digital health integration, and personalized medicine, driving innovation in core medical technology segments. |
Metrics to compare | BDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBDXPeersSector | |
---|---|---|---|---|
P/E Ratio | 32.9x | 38.7x | −0.4x | |
PEG Ratio | 2.34 | 0.88 | 0.00 | |
Price/Book | 2.0x | 4.5x | 2.6x | |
Price / LTM Sales | 2.4x | 3.5x | 3.1x | |
Upside (Analyst Target) | 13.8% | 18.7% | 51.1% | |
Fair Value Upside | Unlock | −12.7% | 8.9% | Unlock |